Related Experiment Videos

Impact of HMG-CoA reductase inhibitors for non-treated coronary segments

Hiroki Nishioka1, Kenei Shimada, Toru Kataoka

  • 1Department of Internal Medicine and Cardiology, Osaka City University, Graduate School of Medicine, Japan. m1153231@med.osaka-cu.ac.jp

Osaka City Medical Journal
|April 12, 2005
PubMed

Insights

Statin therapy significantly reduced coronary plaque volume and increased lumen volume after stenting over six months. This indicates statins stabilize coronary lesions without causing adverse vessel enlargement.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Biology

Background:

  • HMG-CoA reductase inhibitors (statins) are known to reduce coronary events.
  • The precise mechanism of statin's effect on coronary plaque remains unclear.
  • Understanding statin's impact on plaque is crucial for optimizing cardiovascular disease management.

Purpose of the Study:

  • To investigate the effect of statin therapy on coronary plaque volume.
  • To analyze changes in coronary plaque using serial intravascular ultrasound (IVUS) analysis.
  • To determine if statins influence plaque volume without affecting vessel size.

Main Methods:

  • A study involving 48 patients post-coronary artery stenting, divided into statin and control groups.
  • Serial IVUS imaging performed immediately after stenting and at 6-month follow-up.
  • Measurement of external elastic membrane volume (EEMV), lumen volume (LV), and plaque volume (PV) using Simpson's method.

Main Results:

  • The statin group showed a significant reduction in plaque volume (PV) and a significant increase in lumen volume (LV) over 6 months.
  • No significant changes in EEMV were observed in the statin group, indicating no positive vessel remodeling.
  • The statin group exhibited a greater percentage reduction in PV compared to the control group.

Conclusions:

  • Statin administration for six months effectively reduces coronary plaque volume.
  • The observed plaque reduction occurs without inducing positive vessel remodeling.
  • These findings support the role of statins in stabilizing coronary artery lesions.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...